Ken Griffin Immutep LTD Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.87 - $3.23 $8,602 - $14,858	-4,600 Reduced 83.64%	900 $1,000
Q1 2024 May 15, 2024	BUY	$2.11 - $2.89 $7,385 - $10,115	3,500 Added 175.0%	5,500 $12,000
Q4 2023 Feb 14, 2024	SELL	$1.76 - $2.49 $1,056 - $1,494	-600 Reduced 23.08%	2,000 $4,000
Q3 2023 Nov 14, 2023	SELL	$1.75 - $2.37 $18,725 - $25,359	-10,700 Reduced 80.45%	2,600 $4,000
Q2 2023 Aug 14, 2023	SELL	$1.54 - $2.62 $11,858 - $20,174	-7,700 Reduced 36.67%	13,300 $28,000
Q1 2023 May 15, 2023	BUY	$1.63 - $2.06 $2,445 - $3,090	1,500 Added 7.69%	21,000 $35,000
Q4 2022 Feb 14, 2023	BUY	$1.6 - $2.53 $31,200 - $49,334	19,500 New	19,500 $34,000

2.38M

526K

222K

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $178M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.